Tirzepatide+

A revolutionary new FDA approved treatment to help you lose weight and keep it off.

More than just weight loss!

Tirzepatide+ improves on just Tirzepatide

What is Tirzepatide+?

Approved in March 2022 by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.

In comparative head-to-head trials, Tirzepatide surpassed the HbA1c reduction of Semaglutide by an additional 24%. 

According to data from Phase III trial results in patients with type 2 diabetes, Tirzepatide was non-inferior and superior to Semaglutide with respect to the mean change in HbA1c from baseline to 40 weeks.

The Benefits of Tirzepatide+

Tirzepatide+ helps you lose weight by changing the hormone balance of the body. When paired with healthy eating habits and lifestyle changes, Tirzepatide can help you lose weight and keep the weight off. Our formulation of Tirzepatide also includes peptide BPC-157, a bio-identical protective compound that is used to create a more balanced treatment.

 At all doses, Tirzepatide (5mg, 10mg, 15mg) also outperformed Semaglutide (1mg) in body weight reduction after 40-weeks. At 5mg, up to 80% of users achieved at least a 5% (15lb) reduction in body weight; at 10mg, 45% reached a 10% (20lb) reduction; and at 15mg, up to 36% of users achieved at least a 15% (25lb) reduction in body weight compared to 54%, 24%, and 8% of Semaglutide users, respectively.

Weight decrease from baseline after 40-weeks reveals that Tirzepatide (5mg, 10mg, 15mg) offers at least 30%, 60%, and up to 95% more weight loss, respectively, vs. Semaglutide 1mg.

As a GIP and GLP-1 receptor agonist, Tirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. At therapeutic doses, it acts on centers in the brain and suppresses appetite. Used in conjunction with diet and exercise, Tirzepatide helps patients adhere to a reduced-calorie diet, enhancing the weight loss process.

Frequently Asked Questions

  • Month 1: 2.5mg once weekly
  • Month 2: 5mg once weekly
  • Month 3: 7.5mg once weekly
  • Month 4: 10mg once weekly
  • Month 5: 12.5mg once weekly
  • Month 6: 15mg once weekly
Obesity is classified as a systemic inflammatory condition (metaflammation) and long-term weight loss is difficult due to the unaddressed underlying systemic inflammation. This metabolic inflammatory state is associated with reduced levels of adiponectin, which is important in improving insulin sensitivity, reducing metabolic abnormalities, and adjusting the energy expenditure. BPC-157 can address key components of the underlying inflammation with the hope for more sustained weight loss and better systemic health.
BPC-157 is different from Tirzepatide. It stands for Body Protection Compound 157, a peptide chain of 15 amino acids. It is based on a protective compound present in the human stomach. BPC-157 has been studied for decades for its role as an anti-inflammatory agent. It is administered along with Tirzepatide to create a more complete and balanced treatment for your body, with each drug enhancing the effects of the other.

Like with any medication or treatment, there are a number of health risks associated with Tirzepatide+. The most common side effects may include nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, gas, and heartburn.

More serious side effects may include:

  • Pancreatitis (inflammation of the pancreas)
  • Gallbladder problems
  • Kidney problems/failure
  • Serious allergic reactions
  • Increased heart rate
  • Depression

Get Tirzepatide+ From Us

Schedule an appointment and see what Tirzepatide+ can do for you!
Click Here